The report provides market dynamics and trends related to the global HIV drugs market. In addition, it presents the estimations and forecast of the market. The study estimates the revenue generated from the sales of HIV drugs products; however, it excludes the HIV drugs service revenue. The valuations comprise revenue generated from HIV drugs products such as into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors - CCR5 co-receptor antagonist, and HIV integrase strand transfer inhibitors. Furthermore, the report excludes revenue generated from post-sale services of HIV drugs products.

CHAPTER 1: INTRODUCTION 

CHAPTER 2: EXECUTIVE SUMMARY 

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS

CHAPTER 5: HIV DRUGS MARKET, BY REGION

CHAPTER 6: COMPANY PROFILES